Strategic area of application
Human Medicine
Application market
Infectiology - Parasitology
Activities
Therapeutics, Pharma or Biotech
Technologies
Vaccine
Presentation of company's activity
Sanofi Pasteur is the vaccines division of Sanofi, a global biopharmaceutical company focused on human health, dedicated to supporting people through their health challenges. A world leader in the vaccine industry, Sanofi Pasteur offers a broad range of vaccines, protecting against infectious diseases.
Each year, Sanofi Pasteur provides more than 1 billion doses of vaccine, making it possible to immunize more than 500 million people across the globe.
SANOFI PASTEUR: A GLOBAL COMPANY
Headquarters: Lyon, France
Revenue: 4,577 million euros in 2016
R&D and industrial sites worldwide : 15 production and/or R&D sites located in Marcy l'Etoile and Val de Reuil, France; in Cambridge, Canton, Orlando, Rockville, and Swiftwater, USA; in Toronto, Canada; in Pilar, Argentina; in Shenzhen, China; in Hyderabad, India ; in Ocoyoacac, Mexico and in Chachoengsao, Thailand ; and two new facilities under construction in Neuville, France; and Shenzhen, China.
Key features of company
Our Assets:
A broadest vaccine portfolio in the industry
A global presence
A leadership position in five areas: influenza, pediatric combinations, meningitis, travel and endemic vaccines, and boosters
R&D: more than €1 million invested per day and a promising pipeline with 12 vaccines in development
Significant on-going investments to expand production capacity
At the forefront of the immunization community(WHO, UNICEF, PAHO, CDC, GAVI Alliance, AAP, etc.)
Recent news
The New England journal of medicine publishes results of final landmark phase iii efficacy clinical study of Sanofi Pasteur’s dengue vaccine candidate – November 2014
Sanofi Pasteur and immune design collaborate on a vaccine to treat herpes simplex virus– October 2014
Shantha’s investigational rotavirus vaccine enters phase iii clinical trials in India – October 2014
Sanofi Pasteur announces publication of positive data for fluzone® high-dose vaccine in the New England journal of medicine – August 2014
Collaboration framework
Sanofi Pasteur is interested in partners who will share the company's pursuit of innovation and drive for excellence, while becoming a part of its market success story. We welcome the opportunity to evaluate technologies related to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for infectious and chronic diseases.
Partnership opportunity
Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization, as well as technologies supporting product development and industrial performance, including:
- - Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases
- - Agents to enhance vaccine immune responses
- - Characterization and assay of immune responses and disease markers
- - Tools for improving vaccine and monoclonal antibody research, development and production
In-licencing opportunity
In the field of immunology, microbiology, vaccine
